Excipient capacity & portfolio expansion in FMC plans Excipient capacity & portfolio expansion in FMC plans 04-Aug-2011 By Nick Taylor FMC plans to add controlled release technologies and expand excipient production to drive growth at its BioPolymer unit.
FMC deal worth up to $160m, says BioProgress FMC deal worth up to $160m, says BioProgress 04-Feb-2004 Tablet-coating specialist BioProgress formalised its agreement with US chemicals and machinery group FMC in deal that could be worth up to $160 million (€128m) in revenues in the first six years.